Bristol Myers Squibb has sued the Biden administration over payment terms for hospitals in the 340B Drug Discount Program.

The federal 340B Drug Pricing Program — a noble idea first enacted in 1992 — needs to be brought back into the shop for ...

Proposition 34 confronts the longtime abuse of the federal 340B prescription drug program and will hold bad actors ...

Sanofi plans to phase in its own rebate model for 25 drugs — including anti-inflammatory injectable Dupixent, one of the top ...

Minnesota has becomes the first state to release a report examining the 340B drug discount program for "safety-net" hospitals ...

The 340B program's “covered entities” serve low-income, poorer populations that tend to be un- or underinsured. Many, if not ...

The 340B program has received its share of criticisms, largely due to the lack of transparency into covered entities who ...

Despite rebukes by two federal circuit courts, an HHS sub-agency continues to overstep its authority when administering a ...

Bristol Myers Squibb Co. is challenging a federal health agency for denying its plan to implement a rebate model for its ...

Minnesota releases a report on the 340B Drug Pricing Program, highlighting the need for transparency in healthcare economics.

Johnson & Johnson seeks to charge 340B-enrolled disproportionate share hospitals full price for Xarelto and Stelara and issue ...

Sanofi joins Eli Lilly and Johnson & Johnson in seeking to change the 340B drug pricing program, facing pushback from HRSA and healthcare organizations.